{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894646959232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2174/156802607782507402"}},{"identifier":{"@type":"URI","@value":"http://eurekaselect.com/article/download/81878"}},{"identifier":{"@type":"PMID","@value":"17979786"}}],"dc:title":[{"@value":"Recent Advances in the Development of Amyloid Imaging Agents"}],"description":[{"notation":[{"@value":"Excessive amyloid-beta (Abeta) deposition in the brain is one of the most crucial events in the early pathological stage of Alzheimer's disease (AD). Therefore, Abeta deposits have enough potential to become a useful biomarker for not only an early diagnosis of AD, but also for the assessment of the clinical efficacy of anti-Abeta therapies, if they can be measured non-invasively and reliably in living patients. As a potent candidate technique to measure this biomarker, PET amyloid imaging using a radioligand for Abeta deposits has received much attention. A large number of Abeta ligands have been synthesized and evaluated as candidates for amyloid imaging agents. These can be classified into six categories of derivatives: Congo-red, Thioflavine T, stilbene, vinylbenzoxazole, DDNP, and miscellaneous. Many of these derivatives exhibit high binding affinities to Abeta fibrils (below 20 nM) and some of them also show excellent brain pharmacokinetic profiles. The concept of amyloid imaging is currently being tested in human PET studies using optimized amyloid imaging agents. Despite the small number of subjects, these studies have demonstrated sufficiently promising results. This review article provides an overview of recent advances in the development of amyloid imaging agents, and includes: a summary of the fundamental basis and clinical significance of amyloid imaging; lists of binding affinity data for 135 compounds classified into 12 molecular frameworks; a comprehensive discussion of the in vitro and in vivo features of representative Abeta ligands; and a discussion of the current state of clinical evaluation of these amyloid imaging agents (PIB, SB-13, BF-227, and FDDNP)."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825894646959233","@type":"Researcher","foaf:name":[{"@value":"Shozo Furumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894646959232","@type":"Researcher","foaf:name":[{"@value":"Nobuyuki Okamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894646959234","@type":"Researcher","foaf:name":[{"@value":"Ren Iwata"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894646959237","@type":"Researcher","foaf:name":[{"@value":"Kazuhiko Yanai"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894646959235","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Arai"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894646959236","@type":"Researcher","foaf:name":[{"@value":"Yukitsuka Kudo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15680266"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/15680266"}],"prism:publicationName":[{"@value":"Current Topics in Medicinal Chemistry"}],"dc:publisher":[{"@value":"Bentham Science Publishers Ltd."}],"prism:publicationDate":"2007-09-01","prism:volume":"7","prism:number":"18","prism:startingPage":"1773","prism:endingPage":"1789"},"reviewed":"false","url":[{"@id":"http://eurekaselect.com/article/download/81878"}],"createdAt":"2007-11-12","modifiedAt":"2015-11-23","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Radioisotopes","dc:title":"Radioisotopes"},{"@id":"https://cir.nii.ac.jp/all?q=Amyloid%20beta-Peptides","dc:title":"Amyloid beta-Peptides"},{"@id":"https://cir.nii.ac.jp/all?q=Contrast%20Media","dc:title":"Contrast Media"},{"@id":"https://cir.nii.ac.jp/all?q=Ligands","dc:title":"Ligands"},{"@id":"https://cir.nii.ac.jp/all?q=Alzheimer%20Disease","dc:title":"Alzheimer Disease"},{"@id":"https://cir.nii.ac.jp/all?q=Positron-Emission%20Tomography","dc:title":"Positron-Emission Tomography"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Coloring%20Agents","dc:title":"Coloring Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Biomarkers","dc:title":"Biomarkers"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232537384576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Biomathematical screening of amyloid radiotracers with clinical usefulness index"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239453796864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Imaging Protein Misfolding in the Brain Using β-Sheet Ligands"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865561242112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Design, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565170417854336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel <sup>18</sup>F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181146249472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182360812416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656381389952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A 18F-Labeled BF-227 Derivative as a Potential Radioligand for Imaging Dense Amyloid Plaques by Positron Emission Tomography"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656401577728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660550424960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Brain accumulation of amyloid β protein visualized by positron emission tomography and BF‐227 in Alzheimer's disease patients with or without diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661731434880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204272501504","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"アミロイド斑の生体イメージング"},{"@language":"en","@value":"In vivo imaging of amyloid plaques"},{"@language":"ja-Kana","@value":"アミロイド ハン ノ セイタイ イメージング"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204275170688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"アルツハイマー病理を標的とした分子イメージングプローブの開発"},{"@language":"en","@value":"Development of molecular imaging probe targeted at Alzheimer’s disease pathology"},{"@language":"ja-Kana","@value":"アルツハイマー ビョウリ オ ヒョウテキ ト シタ ブンシ イメージングプローブ ノ カイハツ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679251672064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"アミロイドイメージング・タウイメージングの現状と展望"},{"@language":"en","@value":"Amyloid and tau imaging, its present and future"},{"@value":"実験技術 アミロイドイメージング・タウイメージングの現状と展望"},{"@language":"ja-Kana","@value":"ジッケン ギジュツ アミロイドイメージング ・ タウイメージング ノ ゲンジョウ ト テンボウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680345594496","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"臨床試験とバイオマーカー　　３．脳神経疾患におけるバイオマーカー"},{"@language":"en","@value":"3. Biomarkers of Neurological Disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.2174/156802607782507402"},{"@type":"OPENAIRE","@value":"doi_dedup___::31cbd599a65b17905343edee089b6676"},{"@type":"CROSSREF","@value":"10.1016/j.trci.2017.08.006_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.3389/fnins.2018.00585_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.2967/jnumed.112.117341_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.3999/jscpt.41.101_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1254/fpj.131.333_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1254/fpj.150.172_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.3987/rev-22-999_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1007/s00259-012-2261-2_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1007/s11307-012-0608-5_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1007/s11604-013-0276-7_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1111/j.1447-0594.2012.00880.x_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1186/2191-219x-3-32_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1016/j.nucmedbio.2015.05.001_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"},{"@type":"CROSSREF","@value":"10.1254/fpj.146.144_references_DOI_5RyxbsWVtsPYb32Zls4WB3Y5DZt"}]}